Mechanisms of EGFR Resistance in Glioblastoma. Review uri icon

Overview

abstract

  • Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite numerous efforts to target epidermal growth factor receptor (EGFR), commonly dysregulated in GBM, approaches directed against EGFR have not achieved the same degree of success as seen in other tumor types, particularly as compared to non-small cell lung cancer (NSCLC). EGFR alterations in glioblastoma lie primarily in the extracellular domain, unlike the kinase domain alterations seen in NSCLC. Small molecule inhibitors are difficult to develop for the extracellular domain. Monoclonal antibodies can be developed to target the extracellular domain but must contend with the blood brain barrier (BBB). We review the role of EGFR in GBM, the history of trialed treatments, and the potential paths forward to target the pathway that may have greater success.

publication date

  • November 11, 2020

Research

keywords

  • Brain Neoplasms
  • ErbB Receptors
  • Glioblastoma

Identity

PubMed Central ID

  • PMC7696540

Scopus Document Identifier

  • 85095989524

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.21586

PubMed ID

  • 33187135

Additional Document Info

volume

  • 21

issue

  • 22